L8668

Levetiracetam

≥98% (HPLC), powder, antiepileptic

• Sinónimos: (αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(S)-(2-oxopyrrolidin-1-yl)butyramide
• Fórmula empírica (notación de Hill): C₈H₁₄N₂O₂
• Número de CAS: 102767-28-2
• Peso molecular: 170.21
• MDL number: MFCD03265610
• UNSPSC Code: 12352200
• PubChem Substance ID: 329817665
• NACRES: NA.77

Propiedades

• product name: Levetiracetam, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white
• solubility: H₂O: >5 mg/mL
• originator: UCB Inc.
• SMILES string: CC[C@H](N1CCCC1=O)C(N)=O
• InChI: 1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
• InChI key: HPHUVLMMVZITSG-LURJTMIESA-N
• Gene Information: human ... CACNA1B(774) , SV2A(9900)

Descripción

General description

Levetiracetam is a member of the pyrrolidone family, which is a second-generation anti-epileptic drug (AED). It acts as a neuroprotective and hyperalgesic drug. Levetiracetam is implicated in cholinergic neurotransmission.

Application

Levetiracetam has been used as an anti-epileptic drug to study its effects on glucose-mediated death.

Biochem/physiol Actions

Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves